The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells

Cancer Prevention Research

Volumn 2, Issue 12, 2009, Pages 1088-1099

  Kambe, Atsushi ^a,b   Yoshioka, Hiroki ^a,b   Kamitani, Hideki ^b   Watanabe, Takashi ^b   Baek, Seung Joon ^c   Eling, Thomas E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b TOTTORI UNIVERSITY   (Japan)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACTIVATING TRANSCRIPTION FACTOR 3; CELL PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROTEIN EP4; PROTEIN NAG 1; RECEPTOR PROTEIN; SULINDAC SULFIDE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DRUG DERIVATIVE; FLAVONOID; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NAG PROTEIN, HUMAN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE; PROSTAGLANDIN SYNTHASE INHIBITOR; SMALL INTERFERING RNA; SULINDAC; TUMOR PROTEIN;

AGAR MEDIUM; ARTICLE; BINDING SITE; CANCER CELL; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; BRAIN TUMOR; CLONOGENIC ASSAY; DRUG ANTAGONISM; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 3; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; BRAIN NEOPLASMS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CHROMATIN IMMUNOPRECIPITATION; COLONY-FORMING UNITS ASSAY; CYCLOOXYGENASE INHIBITORS; EARLY GROWTH RESPONSE PROTEIN 1; FLAVONOIDS; GLIOBLASTOMA; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RECEPTORS, PROSTAGLANDIN E; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; SULINDAC; TUMOR CELLS, CULTURED;

EID: 76549087130     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0140     Document Type: Article

References (37)

1. Henson JW. Treatment of glioblastoma multiforme: a new standard. Arch Neurol 2006;63:337-41.
2. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001;61:4375-81.
3. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282:1254-7.
4. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
5. Erkinheimo TL, Lassus H, Finne P, et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004;10:538-45.
6. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59: 987-90.
7. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Δ716) knockout mice. Nat Med 2001;7:1048-51.
8. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
9. 2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogenactivated protein kinase and protein kinase C. J Neurochem 2001;79:950-8.
10. Raza SM, Fuller GN, Rhee CH, et al. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res 2004; 10:212-21.
11. Levin VA, Giglio P, Puduvalli VK, et al. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 2006;78:85-90.
12. Ishibashi M, Bottone FG, Jr., Taniura S, Kamitani H, Watanabe T, Eling TE. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin γ1 in human glioblastoma cells. Exp Cell Res 2005;302:244-52.
13. Lee HC, Park IC, Park MJ, et al. Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J Cell Biochem 2005;94:597-610.
14. Lee SH, Yamaguchi K, Kim JS, et al. Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 2006;27:972-81.
15. Kim JS, Baek SJ, Sali T, Eling TE. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 2005;4:487-93.
16. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005;67: 356-64.
17. Fawcett TW, Martindale JL, Guyton KZ, Hai T, Holbrook NJ. Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to regulate Gadd153 expression during the stress response. Biochem J 1999;339: 135-41.
18. Baek SJ, Kim JS, Nixon JB, DiAugustine RP, Eling TE. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004;279:6883-92.
19. Lee SH, Bahn JH, Choi CK, et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 2008;7:3739-50.
20. Han S, Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 2004;314:1093-9.
21. 2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein β. J Biol Chem 2005;280: 33240-9.
22. Kambe A, Iguchi G,Moon Y, Kamitani H,Watanabe T, Eling TE. Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents. Biochim Biophys Acta 2008; 1783:1211-9.
23. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-8.
24. Bottone FG, Jr., Martinez JM, Collins JB, Afshari CA, Eling TE. Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis. J Biol Chem 2003;278:25790-801.
25. Biggs JR, Kudlow JE, Kraft AS. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 1996;271:901-6.
26. Foord SM, Marks B, Stolz M, Bufflier E, Fraser NJ, Lee MG. The structure of the prostaglandin EP4 receptor gene and related pseudogenes. Genomics 1996;35:182-8.
27. Milanini-Mongiat J, Pouyssegur J, Pages G. Identification of two Sp1 phosphorylation sites for p42/ p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002;277:20631-9.
28. Bottone FG, Jr., Moon Y, Alston-Mills B, Eling TE. Transcriptional regulation of activating transcription factor 3 involves the early growth response-1 gene. J Pharmacol Exp Ther 2005;315:668-77.
29. Baek SJ, Eling TE. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 2006;45:1-16.
30. Eling TE, Baek SJ, Shim M, Lee CH. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006;39:649-55.
31. 2 receptor type 4 (EP4) in pregnant cervical tissue. Am J Obstet Gynecol 2003;189:1501-10.
32. Bonello MR, Khachigian LM. Fibroblast growth factor-2 represses platelet-derived growth factor receptor-α (PDGFR-α) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-α promoter. J Biol Chem 2004;279:2377-82.
33. Chu S, Ferro TJ. Sp1: regulation of gene expression by phosphorylation. Gene 2005;348:1-11.
34. Fischer C, Sanchez-Ruderisch H, Welzel M, et al. Galectin-1 interacts with the α5β1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 2005;280: 37266-77.
35. Karlseder J, Rotheneder H, Wintersberger E. Interaction of Sp1 with the growth- and cell cycleregulated transcription factor E2F. Mol Cell Biol 1996;16:1659-67.
36. Bottone FG, Jr., Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE. The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther 2005;4:693-703.
37. Bae MA, Song BJ. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 2003;63:401-8.